Brentuximab Vedotin Plus Lenalidomide and Rituximab for the Treatment of Relapsed/Refractory DLBCL
A phase 3 trial of Brentuximab vedotin, Rituximab, Lenalidomide in diffuse large b-cell lymphoma, run by Seagen, a wholly owned subsidiary of Pfizer, active and no longer recruiting.
Overview
Brentuximab Vedotin Plus Lenalidomide and Rituximab for the Treatment of Relapsed/Refractory DLBCL is a phase 3 interventional study registered as NCT04404283 by Seagen, a wholly owned subsidiary of Pfizer, with 239 participants enrolled, started 2020-08-20 and due to reach its primary completion in 2026-01-23. Interventions recorded: Brentuximab vedotin, Rituximab, Lenalidomide, Placebo. Conditions listed: Diffuse Large B-cell Lymphoma. No results are recorded here; the registry entry is the source.
Similar pages
not linked directly; found by shared links- TrialA Novel Vaccine (EO2463) as Monotherapy and in Combination, for Treatment of Patients With Indolent Non-Hodgkin Lymphoma
Shares Lenalidomide, Rituximab.
- TrialA Study of Rocbrutinib in Participants With Relapse or Refractory Non-GCB Diffuse Large B-Cell Lymphoma
Shares Lenalidomide, Rituximab, Diffuse large B-cell lymphoma.
- CompanyBiogen
Shares Rituximab, Diffuse large B-cell lymphoma.
- TrialA Study of Subcutaneously Injected Epcoritamab Plus Oral Lenalidomide Tablets Compared to Intravenously (IV) Infused Rituximab Plus IV Infused Gemcita
Shares Lenalidomide, Rituximab, Diffuse large B-cell lymphoma.
- TrialL-MIND
- TrialStudy With Elranatamab Versus Lenalidomide in Patients With Newly Diagnosed Multiple Myeloma After Transplant
Shares Lenalidomide, Pfizer (incl. Seagen).
- TrialEfficacy and Safety of Orelabrutinib Combined With Rituximab Versus Lenalidomide Combined With Rituximab in Patients With Relapsed/Refractory Marginal Zone Lymphoma
Shares Lenalidomide, Rituximab.
- TrialStudy of Acalabrutinib and Rituximab in Untreated Elderly and/or Frail Patients With DLBCL
Shares Rituximab, Diffuse large B-cell lymphoma.